The Absolute Effect / Oncology Evidence / Evidence Index
PAPILLON
In untreated advanced NSCLC with EGFR exon 20 insertion, does amivantamab plus carboplatin-pemetrexed improve progression-free survival over chemotherapy?
Registry: NCT04538664 · Evidence reviewed 9 November 2026 · Aliases and follow-up publications consolidated.
Phase III randomized open-label; n=308.Primary-source evidence summaryStudy design, population and eligibility
Phase III randomized open-label; n=308.
Untreated advanced NSCLC with EGFR exon20 insertion.
Treatment and comparator
Intervention: Amivantamab + carboplatin/pemetrexed.
Comparator: Carboplatin/pemetrexed; crossover allowed.
Endpoints
PFS by BICR primary.
Key efficacy and clinical outcomes
Median PFS 11.4 vs 6.7 mo (HR 0.40); ORR 73% vs 47%; interim OS HR 0.67 (0.42–1.09).
Source-reported outcome visualization
Values are reproduced from the cited report; bars are scaled within this figure. First-line EGFR exon20 insertion-mutated advanced NSCLC
Median survival and hazard ratios are not fixed-time event risks; NNT is not inferred from them.
Toxicity and treatment burden
Infusion reactions, rash, paronychia and EGFR toxicity plus platinum-pemetrexed effects.
Absolute effect and NNT/NNH
Molecularly specific exon20 population; OS immature at primary report.
NNT/NNH is not calculated unless a directly reported, comparable fixed-time risk difference supports it. Median survival and hazard ratios alone do not provide an NNT.
Critical interpretation and limitations
Molecularly specific exon20 population; OS immature at primary report.
This page is an evidence summary, not a substitute for multidisciplinary assessment or patient-specific decision-making.
Current-practice context
Review date: 9 November 2026. Primary publication and selected follow-up sources were reviewed. Full disease-specific guideline, regulatory-label and sequencing audit remains pending; verify current local recommendations and biomarker eligibility before clinical application.